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Abstract. Several previous studies have demonstrated that 
aged garlic extract (AGE) inhibits the progression of coronary 
artery calcification and non-calcified plaque (NCP) in the 
general population. However, its effects on plaque progression 
in patients with diabetes have not yet been investigated, at least 
to the best of our knowledge. This study investigated whether 
AGE reduces the coronary plaque volume measured by cardiac 
computed tomography angiography (CCTA) in patients with 
diabetes mellitus (DM). A total of 80 participants with DM 
with a median age of 57 years were prospectively assigned 
to consume 2,400 mg AGE/day (after completion, 37 partici-
pants) or placebo (after completion, 29 participants) orally. 
Both groups underwent CCTA at baseline and follow-up 
365 days apart. In total, 66 participants completed the study. 
Coronary plaque volume, including total plaque (TP), dense 
calcium (DC), fibrous, fibro‑fatty and low‑attenuation plaque 
(LAP) volumes were measured based upon pre‑defined inten-
sity cut-off values using semi-automated software (QAngio 
CT). Changes in various plaque types were normalized to the 
total coronary artery length. The non-parametric Wilcoxon 
rank-sum test was performed to examine the differences in 
plaque formation between the 2 groups. No significant differ-
ences were found in the baseline characteristics between the 
AGE and placebo groups. Compared with the placebo group, 
the AGE group exhibited a statistically significant regression 
in normalized LAP [median and standard deviation (SD) -0.2 
(18.8) vs. 2.5 (69.3), P=0.0415]. No differences were observed 
in TP, fibrous, or fibrofatty plaque volumes between the AGE 
and placebo group. On the whole, this study indicated that the 
%LAP change in the AGE group was significantly greater than 
that in the placebo group in patients with diabetes. However, 
further studies are warranted to evaluate whether AGE has 
the ability to stabilize vulnerable plaque and decrease adverse 
cardiovascular events.
Introduction
Coronary artery disease (CAD) is the leading cause of morbidity 
and mortality in individuals with diabetes. According to the 
report of the American Diabetes Association (ADA), the esti-
mated cost related to the treatment of cardiovascular event is 
$37.3 billion annually in individuals with diabetes in the US 
alone (1). Unfortunately, however, the incidence of diabetes is 
increasing in epidemic proportions worldwide. It is estimated 
170 million individuals are living with diabetes worldwide 
and its prevalence is estimated to double by 2030 (2). A 
previous study demonstrated that the risk of mortality from 
cardiovascular causes in subjects with type 2 diabetes mellitus 
(T2DM) and no previous history of cardiovascular events 
is equivalent to that of non-DM subjects with prior myocar-
dial infarction (MI) (3). Asymptomatic atherosclerosis has 
usually been present for years and even decades prior to the 
development of clinical evidence of CAD (4,5). Screening for 
the early detection of patients who are at risk of developing 
asymptomatic atherosclerosis and monitoring their response 
to treatment in order to reduce cardiovascular events remains a 
major challenge in preventive cardiology. Coronary computed 
tomography angiography (CCTA) is considered a reliable 
tool with which to detect or rule out the presence, extent and 
severity of coronary atherosclerosis (6).
Previous studies demonstrated that statin and anti-diabetic 
therapies may decrease the rate of coronary plaque progres-
sion and may participate in plaque stabilization (7-9). Previous 
experiments performed in our laboratory have shown that the 
use of aged garlic extract (AGE) is associated with a signifi-
cant reduction in low attenuation plaque (LAP) progression 
as compared to the placebo using CCTA in patients with 
metabolic syndrome (10). Furthermore, AGE has been shown 
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to exert positive effects on several cardiovascular disease risk 
factors, including endothelial dysfunction, cholesterol and 
blood pressure (11-14). The aim of the present study was to 
evaluate the effects of AGE over a period of 1 year on coronary 
atherosclerotic plaque in individuals with T2DM utilizing 
CCTA.
Patients and methods
Study design. This study was a single-center, randomized, 
placebo-controlled, double-blind trial being conducted at 
the Lundquist Institute for Biomedical Innovation at Harbor 
UCLA Medical Center. In total, 80 individuals, who met 
the eligibility criteria (inclusion and exclusion criteria) were 
enrolled in this study. After signing a written informed 
consent, cardiovascular risk factors and blood samples were 
collected following a 12‑h fast. Sample were stored at ‑70˚C 
and analyzed for hemoglobin A1c (HbA1c) levels and lipid 
profiles, including serum low-density lipoprotein (LDL) 
cholesterol, high-density lipoprotein (HDL) cholesterol and 
triglycerides (TGs), with the use of automated diagnostic 
equipment (DLS Laboratories). All participants underwent 
CAC scanning and CCTA to evaluate early CAD. Patients 
were randomized at a 1:1 ratio to receive 2,400 mg AGE/day 
or a placebo. The intended duration of administration for 
the study group was 12 months. This study was approved 
by the Institutional Review Board of Lundquist Institute for 
Biomedical Innovation at Harbor UCLA Medical Center 
(Clinicaltrials.gov: NCT03931434).
Inclusion criteria. Patients with T2DM were enrolled in this 
study. The age of the patients was between 30-75 years and the 
patients had HbA1c levels >6.5% or fasting blood sugar levels 
>125 mg/dl, or were taking anti-diabetic medications and who 
provided the written informed consent.
Exclusion criteria. Individuals with known hypersensitivity 
to AGE, a body weight >300 lbs, a history of bleeding disor-
ders or those taking anti-coagulants, those with hypertensive 
encephalopathy or cerebrovascular event, a known history 
of CAD, MI, stroke or life-threatening arrhythmia within 
the prior 6 months, New York Heart Association Functional 
Classification II‑IV heart failure, renal impairment (serum 
creatinine levels, >1.4 mg/dl), current tobacco use, or who 
were currently enrolled in another placebo-controlled trial or 
females with pregnancy were excluded.
Outcome measures. The outcome measures included the rate 
of change in coronary plaque volume and vulnerable compo-
nent of coronary plaques.
AGE. AGE (Kyolic) is formulated by soaking sliced raw garlic 
in aqueous ethanol solution at room temperature for up to 
20 months as previously described (11,12). The 2,400 mg of 
AGE capsules were provided by Wakunaga of America Co., 
Ltd. with a matched placebo pill. The placebo and the study 
drug appeared to be of similar size and color; however, the 
placebo pill did not contain any garlic or active ingredient. All 
participants were advised to take 2 capsules twice daily with 
water for 12 months. An inter-trial phone visit was conducted 
to ensure study medication compliance. The AGE capsule 
used in this study is commercially available in the market.
Data acquisition. The details of coronary artery plaque 
volume by CCTA assessment have been published in previous 
studies (6,15). Non-contrast scans for the evaluation of the 
extent of coronary artery calcium and contrast scans for the 
evaluation of coronary artery plaque volume at baseline and 
12 months were acquired. Scans were assessed by readers who 
were blinded both to treatment group and to the date of the 
scan.
Coronary plaque assessment. Quantitative plaque assess-
ment was performed according to a previously defined 
protocol (10) using semi-automated plaque analysis software 
(QAngioCT Research Edition Version 2.0.5; Medis Medical 
Imaging Systems). Based on the guidelines of the Society of 
Cardiovascular Computed Tomography, 17-segment coronary 
artery model vessels based on SCCT guidelines were assessed. 
Only vessels >1.5 mm were evaluated. The volumes of 4 types 
of coronary artery plaque [LAP, fibro‑fatty (FF), fibrous (F) 
and dense calcium (DC)] were calculated using the Hounsfield 
unit threshold.
Statistical analyses. Continuous variables are expressed 
as the means ± standard deviation (SD), while categorical 
variables are stated as counts and percentages. A Student's 
t-test or Chi-square test was used to assess differences in 
all baseline parameters between the placebo and AGE. The 
analysis included comparisons for both plaque levels at both 
baseline and follow-up and between groups following the use 
of the ANOVA modeling with the Tukey approach P-value. 
ANCOVA modeling was also used to adjust for clinically 
significant variables. As none of these modeling techniques 
were significant, we thus chose to focus on the simple progres-
sion of LAP in the placebo group and regression in the active 
group. Atherosclerotic plaque volumes differences between 
the placebo and AGE were assessed by the Wilcoxon rank-sum 
test. A P-value <0.05 was considered to indicate a statistically 
significant difference. SAS software (version 9.4) was used to 
carry out all statistical analyses.
Results
From 2016 to 2017, 80 patients were enrolled and randomly 
assigned to the placebo or AGE groups. In total, 66 patients 
completed the study with baseline and follow-up CT. The 
participants had a mean follow-up period of 370±24 days. Of 
these patients, 28% in the placebo group and 29% in the active 
group were on statins. Patients in both groups continued to 
see their primary care physicians and continued their regular 
medications. All the baseline data at entry into this study in 
both groups have been previously described (16). No statisti-
cally significant differences were found between the groups.
The AGE group compared with the placebo group exhib-
ited a statistically significant regression in normalized LAP 
[median SD) -0.2 (18.8) vs. 2.5 (69.3), P=0.0415]. By percentage, 
there was 29% reduction in LAP in the AGE group as opposed 
to 57% LAP plaque progression in the placebo group. The 
AGE group exhibited a reduction in FF plaque as compared 
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to the progression of FF in the placebo group; however this 
did not reach statistically significance (median difference ‑0.1 
vs. +1.6, P-0.287). No marked differences were observed in 
total plaque (TP), F, or FF plaque volumes between the AGE 
and placebo group (Table I and Fig. 1).
Discussion
In this study, 1 year of AGE therapy was associated with a 
regression of LAP. LAP [non‑calcified plaque (NCP) <30 HU] 
is one of the high-risk plaque features. The results of this 
study are in concordance with those of previously published 
studies demonstrating the regression of LAP in participants 
with metabolic syndrome and general population in studies of 
AGE (10,17), as well as statin studies (18,19).
According to certain data, LAP represents an intravascular 
ultrasound (IVUS) equivalent of the necrotic core (19). In 
contrast to more stable F plaques, plaques with a lipid-rich 
necrotic core play a significant role in the development of 
acute coronary syndrome (ACS) (20). Recent advancements 
in cardiac imaging modalities have provided an accurate and 
detailed quantitative assessment of plaque composition and 
burden based on differences in CCTA (21). Previous studies 
have demonstrated an increased risk of myocardial infarction 
and cardiovascular death in patients with a larger volume of 
non‑calcified and low‑attenuation plaque (22,23).
Motoyama et al (24) demonstrated that patients with ACS 
exhibited a significantly increased frequency of low attenua-
tion plaque (79 vs. 9%, P<0.001). Balestrieri et al (9) reported 
that the patients with stable chest pain with adverse plaque 
features, including LAP, spotty calcification and positive 
remodeling found an association with a 60% increased risk 
Table I. Quantitative plaque scores (median ± SD) in both groups.
Type of  Baseline  Follow-up  Difference with in the group Difference with 
plaque No. (median ± SD) P-value (median ± SD) P-value (median ± SD) in the group (∆ %)
DC   0.61  0.82  
  Placebo  29   29.8±146.7  39.5±169  11.5±33.9 33%
  Active 37 31.6±99.2     53.5±113.8  19.7±29.8 69%
FF   0.81  0.28  
  Placebo  29   34.1±163.7     42.3±174.2  1.6±26 24%
  Active 37 36.9±46.6   23.9±44.3    -0.1±23.5 -35%
F   0.64  0.60  
  Placebo  29    148±288.7    163.4±281.7     14.3±136.6 10%
  Active 37 148.5±193.2    186.3±188.3   21.6±84.5 25%
LAP   0.97  0.04  
  Placebo  29   9.4±85.1      14.8±146.4     2.5±69.3 57%
  Active 37    14±38.3      9.9±33.8    -0.2±18.8 ‑29%
TNCP   0.62  0.62  
  Placebo  29 170.2±516.1    308.7±547.6     25.7±129.4 81%
  Active 37 220.2±243.6    283.4±243.4   26.5±96.7 29%
TPV   0.79  0.50  
  Placebo  29 223.9±595.2    347.9±657.9     53.3±141.2 55%
  Active 37    275±316.7    328.4±313.1     38.7±100.9 19%
Values are the means ± SD. Values in bold font indicate statistically significant differences (P<0.05). DC, dense calcium; FF, fibro‑fatty; F, 
Fibrous; LAP, low‑attenuation plaque; TNCP, total noncalcified plaque; TPV, total plaque volume.
Figure 1. Plaque differences in both groups at 12 months. Percentages 
(%) of coronary atherosclerotic plaque volume changes of dense calcified 
(DC), fibrous fatty (FF), fibrous (F), Low attenuation plaque (LAP), total 
non‑calcified plaque (TNCP) and total plaque (TP)among both the groups 
at 12 months.
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of future adverse cardiovascular events. Furthermore, LAP 
along with other vulnerable plaque features have been shown 
to be associated with rapidly progressive CAD (25). The 
SCOT-HEART trial, which consisted of mostly intermediate 
risk patients, demonstrated that low attenuation was associ-
ated with a 3-fold increased risk of non-fatal MI or coronary 
heart disease-associated mortality (26). In this study, there 
was a 57% increase in low attenuation plaque in the placebo 
group, representing the natural history of plaque progres-
sion. By contrast, a 29% reduction was observed in LAP in 
the AGE group over a period of 1-year follow-up, strongly 
suggesting the therapeutic potential of AGE in the diabetic 
population (Fig. 1).
The present study has several limitations. First, this rela-
tively small sample size and short-term follow-up study did not 
have enough power to demonstrate the significant differences 
in TP volume, NCP and DC. Second, patients were under 
different therapies for hyperlipidemia and T2DM, and some 
patients used varying medications at different doses. Due to 
the small sample size, a separate analysis with different hyper-
lipidemia and T2DM medications was not performed. Further 
research is thus required to evaluate whether AGE has the 
ability to stabilize vulnerable plaque and to decrease adverse 
cardiovascular events.
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